Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2005.471 | Infliximab Induction Therapy for Moderate-to Severe Plaque-Type Psoriasis: An Open-Label, Single Arm Observational Study Evaluating the Efficacy of Use In Hong Kong Chinese Patients | Prof. LUK Tommy Nai Ming |
| 2014.406 | Effects of thromboelastography-guided transfusion algorithm versus standard clinical practice on post-operative bleeding and blood product use after cardiac surgery: a randomized, controlled trial | Dr. LUK Ting Hin |
| 2013.347 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei | Dr. LUK Sally Wai Yin |
| 2011.493 | Hand eczema among inhabilitants of a public housing estate in Hong Kong: a self-administered questionnaire survey | Dr Luk Nai Ming |
| 2008.190 | Efficacy and Safety of Topical Photodynamic Therapy for Actinic Keratosis among Chinese Patients | Dr. LUK Nai Ming |
| 2009.437 | Efficacy of intralesional 5-fluorouracil in treatment of keloid scar : a randomized-control trial | Dr. LUK Nai Ming |
| 2007.318 | Efficacy and Safety of Diphencyprone (DCP) in the Treatment of Extensive Alopecia Areata in Chinese Patient | Dr. LUK Nai Ming |
| 2013.399 | Focused Ultrasound Screening for Precutaneous Dilatational Tracheostomy | Dr. LUK Leona Wing Kun |
| 2009.414 | The effect of visual stimulation on the adult patient | Mr. LUK Kar Yiu |
| 2008.401 | The Effect of Vital Signs Obtained at Prehospital and Emergency Department's Triage Station on Impatient Admission | Miss LUK Joies Ka Yan |
| 2016.035 | Whole–body vibration training for residents in a care and attention home in Hong Kong and its influence on balance and mobility: a pilot study |
Ms. LUK Ho Yan 陸可欣 |
| 2023.237 | Clinical Characteristics and Outcomes of Infections due to carbapenem-resistant Enterobacterales in Hong Kong | Dr. LUK Fion Wing Lam |
| 2007.365 | Longitudinal Change in Mental Competence for Treatment Decision in Chinese Older Adults with Congitive Impairment | Dr. LUK Daisy Nga Yan |
| 2014.385 | Best practice of holistic care: A case study approach | Dr. LUK Andrew Leung |
| 2022.634 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
Prof. LUK Andrea On Yan 陸安欣 |
| 2024.159 | Implementation of a novel diabetes prevention programme in Hong Kong Chinese workforce at high risk of type 2 diabetes | Prof. LUK Andrea On Yan |
| 2021.501 | An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants |
Dr. LUK Andrea On Yan 陸安欣 |
| 2023.314 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION | Prof. LUK Andrea On Yan |
| 2022.404 | Healthcare utilisation and diseases in people with and those without diabetes in Hong Kong before and after COVID-19 pandemic | Prof Luk Andrea On Yan |
| 2021.164 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease. | Dr. LUK Andrea On Yan |
| 2022.148 | A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19 |
Dr. LUK Andrea On Yan 陸安欣 |
| 2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Ms. LUK Andrea On Yan |
| 2017.436 | Single - Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Azilsartan Tablets in Chinese Healthy Volunteers |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.451 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020531 AND METABOLITES FOLLOWING ORAL ADMINISTRATION TO CHINESE HEALTHY VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2014.426 | A STUDY TO EVALUATE THE EFFECT OF BTI320 (SUGARDOWN®) ON POST-PRANDIAL HYPERGLYCAEMIA IN HIGH RISK CHINESE SUBJECTS WITH PRE-DIABETES | Dr. LUK Andrea On Yan |
| 2015.208 | Using C-peptide, anti-glutamic acid decarboxylase antibodies and body mass index to identify patients with young-onset type 2 diabetes for early insulin therapy | Dr. LUK Andrea On Yan |
| 2017.298 | Incidence of diabetes and diabetes-related complications in Hong Kong | Dr. LUK Andrea On Yan |
| 2017.248 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of ranolazine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.167 | Single-center, randomized, double-blind, placebo-controlled, single-dose and multiple-dose, parallel-group study to investigate pharmacokinetics, pharmacodynamics, safety and tolerability of vericiguat in Chinese healthy male subjects under fed condition |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.046 | Interactive effects of testosterone, estradiol and CAG repeat polymorphism of androgen receptor gene on cardiovascular-renal diseases and mortality in men with type 2 diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2018.093 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of Bilastine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.263 | Pharmacokinetics study of Trazodone Hydrochloride Prolonged-release tablets in Chinese Healthy Volunteers | Dr. LUK Andrea On Yan |
| 2016.264 | Single center, randomized, open labeled pharmacokinetics study of Azilsartan Tablets in Chinese healthy volunteers | Dr. LUK Andrea On Yan |
| 2017.271 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR–BLIND, SUBJECT-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO7062931 FOLLOWING SUBCUTANEOUSLY ADMINISTRATION IN HEALTHY CHINESE VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.261 | Establishment of a registry on young-onset diabetes in Asia |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.297 | A Single-dose Pharmacokinetic/Pharmacodynamic, Safety and Tolerability Study of Subcutaneous Evolocumab Supplied by AML-14 Manufacture Site in Healthy Subjects of Chinese Descent |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.733 | Impact of heavy metal exposure during adolescence on glycemic status and cardio-metabolic risk factors in adulthood |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2014.699 | Dose-response study of gevokizumab (S 78989 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled, study. | Dr. LUK Andrea On Yan |
| 2015.634 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY |
Dr. LUK Andrea On Yan 陸安欣 |
| 2014.056 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY | Dr. LUK Andrea On Yan |
| 2020.689 | ReFineDR: Observational study of Routine ophthalmological examinations of patients included in the 2 Bayer sponsored phase 3 clinical trials FIDELIO and FIGARO to investigate the effect of Finerenone on delaying the progression of Diabetic Retinopathy |
Dr. LUK Andrea On Yan 陸安欣醫生 |
| 2020.032 | Health and Economic Impacts of Pre-Diabetes, Gestational Diabetes, Type 1 and Type 2 Diabetes in Hong Kong |
Dr. LUK Andrea On Yan 陸安欣 |
| 2018.232 | Search for Maturity-Onset Diabetes of the Young in Chinese with Young-Onset Diabetes | Dr. LUK Andrea On Yan |
| 2020.132 | A Trial Investigating the Pharmacokinetic Properties of Fast-acting Insulin Aspart in Chinese Subjects with Type 1 Diabetes or Type 2 Diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2020.438 | Delineating the metabolic architecture and response to anti-hyperglycaemic drug treatment in lean type 2 diabetes in Chinese | Dr. LUK Andrea On Yan |
| 2012.482 | Descriptive study of clinical profile of Hong Kong diabetic population | Dr Luk Andrea On Yan |
| 2011.084 | A randomized controlled study to evaluate the effect of n-3 polyunsaturated fatty acids on the progression of diabetic kidney disease | Dr Luk Andrea On Yan |
| 2012.489 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2011.182 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
Page 96 of 254.